autologous clonal neoantigen T cells ATL001

A preparation of personalized tumor-derived T-lymphocytes composed of tumor infiltrating lymphocytes (TILs) that are reactive to clonal cancer neoantigens, with potential immunostimulating and antineoplastic activities. The TILs are removed from the suppressive tumor microenvironment (TME) and re-activated. Upon reintroduction into the patient, the clonal neoantigen T (cNeT) cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.